Latham & Watkins Advises the Underwriters in Halozyme Therapeutics’ Private Offering of Convertible Notes

A capital markets team represents the underwriters in the biopharmaceutical company’s offering.

February 25, 2021

Halozyme Therapeutics, Inc., a leader in converting IV biologics to subcutaneous delivery, announced the pricing of US$700 million aggregate principal amount of its .25% convertible senior notes due 2027. The convertible notes are being offered in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The Company granted an option to the initial purchasers to purchase up to an additional US$105 million aggregate principal amount of convertible notes.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets deal team led by New York partner Greg Rodgers, San Diego partner Michael Sullivan and with associates Jacob Steele, Andrew Blumenthal, Nicholas Reist, and Ty Balzer.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.